HuMax-IL8 for COVID-19: real-time analysis

Download Image

Post

c19early.org

HuMax-IL8 for COVID-19

1 study with 43 patients

Serious outcome risk

HuMax-IL8

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 HuMax-IL8 studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−6%

Mortality (1)−6%

RCTs (1)−6%

Late (1)−6%

00.511.5+

← HuMax-IL8
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


May 22 2025	Stein et al., NCT04347226	A Randomized Phase 2 Study of Anti-IL-8 Therapy Versus Standard of Care in the Treatment of Hospitalized Patients With Severe COVID-19
May 22 2025	6% higher mortality (p=1), 100% higher ICU admission (p=0.59), and 107% slower improvement (p=0.08). RCT 43 hospitalized patients in the USA showing no significant benefit with HuMax-IL8 (BMS-986253) treatment.